Evidence map›Paper›PMID 24450897›Full record

ArticleThe New England journal of medicine2014

Antiamyloid therapy for Alzheimer's disease--are we on the right road?

Eric Karran, John Hardy

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Exploring the Neuroprotective Properties of Celery (Molecules (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity Conference.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Using Alzheimer's disease blood tests to accelerate clinical trial enrollment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  15. PET molecular imaging for pathophysiological visualization in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2023
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Olive Oil Polyphenols in Neurodegenerative Pathologies.Advances in experimental medicine and biology · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Eric KarranFrom Reta Lila Weston Laboratories and the Department of Molecular Neuroscience, University College London, London (E.K., J.H.), and Alzheimer's Research UK, Cambridge (E.K.) - both in the United Kingdom.
John Hardy

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, Monoclonal, HumanizedFemaleHumansMaleAmyloid beta-PeptidesAntibodies, Monoclonal, Humanizedbapineuzumabsolanezumab

Identifiers

PMID24450897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.